ClinicalTrials.gg
CompletedNCT05121441Updated Jan 22, 2025Results posted

Study to Evaluate ARD-101 in Adults With Obesity

A Phase 2 interventional study of ARD-101 and Placebo in Obesity, sponsored by Aardvark Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Aardvark Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.

Read the detailed description

This is a Phase 2, randomized, placebo-controlled study to investigate the effects of ARD-101, a small molecule targeting bitter taste receptors (TAS2Rs), in obese subjects with a body mass index (BMI) of 30-45 kg/m2. This study has a planned enrollment of 30 subjects and will be conducted in a single center in the United States.

The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (End-of-Study Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101 in an outpatient setting and will be instructed to visit the clinical center periodically for safety and efficacy assessments.

02

Conditions studied

  • Obesity

Keywords

  • Obesity
  • Anti-Obesity Agents
  • Body Weight
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 20 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Aardvark Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, 18-75 years of age
  • Willing and able to provide signed and dated prior to any study-related procedures and willing and able to comply with all study procedures
  • of 30-45 kg/m2
  • Stable body weight by subject report (± 5%) in the previous 6 months prior to randomization
  • No abnormal findings or abnormalities of clinical significance in vital signs, physical examination, clinical laboratory tests (complete blood count (CBC), urinalysis, blood biochemistry, coagulation, pregnancy test (females of child bearing potential), urine drug test, nicotine test, etc.), 12-lead (ECG) during the Screening Period.
  • Serum creatinine, alkaline phosphatase, hepatic enzymes (, alanine aminotransferase) and total (unless the subject has documented Gilbert syndrome) not exceeding 1.5-fold the upper laboratory norm and estimated (eGFR) >30 mL/min
  • Standard 12-lead ECG parameters after 10 minutes resting in supine position in the following ranges; 120 ms \<PR \<220 ms, QRS \<120 ms, ≤ 430 ms if male, ≤ 450 ms if female, and normal ECG tracing unless the Investigator considers an ECG abnormality within described limits to be not
  • Stable or well controlled blood pressure per Investigator's judgement during the Screening Period. Specifically: Vital signs after 10 minutes sitting in a chair (feet on floor, back supported):

    i. 95 mmHg \<systolic blood pressure (SBP) \<160 mmHg, ii. 45 mmHg \<diastolic blood pressure (DBP) \<100 mm Hg, iii. 40 bpm \<heart rate (HR) \<100 bpm

  • Prediabetes- defined as a fasting blood glucose between 100-125 mg/dL OR an between 5.7-6.5% at screening
  • Type 2 diabetes- Defined as previous diagnosis by a healthcare professional OR a fasting blood glucose > 126 mg/dL OR HbA1c > 6.5% at screening
  • Patients with type 2 diabetes treated with metformin may be enrolled. However, patients with type 2 diabetes on any other therapy will be excluded
  • Female subjects must have negative serum pregnancy test and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single barrier method (i.e., sponge), or a double-barrier method of (i.e., condom with spermicide) or abstinence must be used/practiced throughout the study and for 90 days following last dose of study medication; for effective form of birth control
  • Females of non-, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, bilateral tubal ligation, bilateral salpingectomy, or bilateral tubal occlusion) or for at least 12 months (may be confirmed with a screening follicle stimulating hormone (FSH) level in the post-menopausal lab range), do not require contraception during the study
  • Males with female partners of childbearing potential must agree to a double-barrier method if they become sexually active during the study and for 90 days following the last dose of the study medication. Male subjects must not donate sperm for 90 days following their participation in the study

Exclusion criteria

Exclusion Criteria:

  • History of significant drug or anaphylaxis
  • Prior bariatric or GI surgery (excluding cholecystectomy, hysterectomy or appendectomy)
  • Participation in a weight loss program or clinical trial for weight loss within 30 days prior to randomization
  • Diabetes treatment (unless metformin as outlined), or chronic oral , or treatment with immune modulators, anti-obesity drugs, chronic opiate therapy, or antipsychotic medications
  • Received any experimental drugs or devices or have participated in a clinical study within 30 days prior to randomization
  • Currently receiving any drug-based therapy for weight management
  • Thyroid-stimulating hormone (TSH) level is outside of normal limit
  • The presence of diseases with abnormal clinical manifestations that need to be excluded based on their possible contribution to weight loss or weight gain, including but not limited to nervous, cardiovascular, blood and lymphatic system, immune, renal, hepatic, gastrointestinal, respiratory, metabolic and skeletal diseases
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, Functional Class II-IV heart failure, or within 6 months prior to Visit 1
  • Any not considered cured (except focal, treated basal cell carcinoma and squamous cell carcinoma of the skin); a participant is considered cured if there has been no evidence of cancer recurrence in the previous 5 years
  • History of major depressive disorder or history of other severe psychiatric disorders (e.g., schizophrenia or bipolar disorder) within the last 2 years.
  • Major surgery within 3 months prior to randomization or planned surgery during the study
  • Donated ≥200 mL of blood (blood components) or had massive blood loss, received blood transfusion or blood products within 3 months prior to randomization
  • Planned sperm/egg donation within 6 months post randomization
  • Positive urine drug test for any illicit non-prescription substances
  • History of consuming more than 14 units of alcoholic beverages per week or of alcoholism or drug/chemical/substance abuse within past 2 years prior to enrollment (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits)
  • Smoking any amount within 3 months prior to randomization
  • Excessive consumption of tea, coffee, and/or caffeinated beverages (more than 8 cups, 250 mL for each cup) every day within 3 months prior to enrollment
  • Symptomatic viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to randomization
  • History of antibody or active hepatitis
  • A history of psychiatric and psychological condition that, in the judgment of the investigator, may interfere with the planned treatment and follow-up, affect subject compliance or place the subject at high risk from treatment-related complications
  • Poor venous access or inability to tolerate venipuncture
  • Any condition or active drug treatment that the investigator or primary physician believes may not be appropriate for participating in the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    ARD-101

    Dose 200 mg of ARD-101, twice daily for 28 days

    Drug: ARD-101

  • Placebo comparator
    Placebo Comparator

    Placebo arm matching active arm ARD-101, 200 mg BID

    Drug: Placebo

Interventions

  • Twice daily, oral administration

  • DrugPlacebo

    Twice daily, oral administration

06

What researchers measure

Primary outcomes

  1. Relative Change in Body Weight (%)

    The percent total weight change at the end of treatment from baseline

    Time frame: Run-in Visit (baseline), Day 28

Secondary outcomes

  1. Incidence (Number) of Treatment-emergent Adverse Events (TEAE)

    The number of treatment-emergent adverse events (TEAE) reported by participants during the treatment period

    Time frame: Days 1-28

  2. Change in TC

    The change in total cholesterol (TC) at the end of treatment from baseline

    Time frame: Days 1 to 28

  3. Change in TG

    The change in triglyceride (TG) at the end of treatment from baseline

    Time frame: Days 1-28

  4. Change in HDL

    The change in high density lipoprotein cholesterol (HDL) at the end of treatment from baseline

    Time frame: Days 1-28

  5. Change in LDL

    The change in low-density lipoprotein cholesterol (LDL) at the end of treatment from baseline

    Time frame: Days 1-28

  6. Change in Waist Circumference

    The change in waist circumference at the end of treatment from baseline

    Time frame: Days 1-28

  7. Change in % HbA1C

    The change in % of hemoglobin A1c (HbA1c) at the end of treatment from baseline

    Time frame: Screening to Day 28

07

Results

Posted Jan 22, 2025

Participant flow

Participants were recruited based on physician referrals at the clinical site between November 2021 and August 2022. A total of 30 subjects were originally planned, but only 20 subjects were enrolled, treated, and analyzed. The first participant was enrolled on November 15, 2021, and the last participant was enrolled in August 2022.

Participant flow — Overall Study
MilestoneARD-101Placebo Comparator
Started146
Completed146
Not completed00

Outcome measures

PrimaryRelative Change in Body Weight (%)

The percent total weight change at the end of treatment from baseline

Time frame:
Run-in Visit (baseline), Day 28
Reported as:
Mean · Percentage of body weight change
Relative Change in Body Weight (%)
Percentage of body weight changeARD-101Placebo Comparator
Relative Change in Body Weight (%)-0.33 ± 0.940.38 ± 1.08
SecondaryIncidence (Number) of Treatment-emergent Adverse Events (TEAE)

The number of treatment-emergent adverse events (TEAE) reported by participants during the treatment period

Time frame:
Days 1-28
Reported as:
Count of participants · Participants
Incidence (Number) of Treatment-emergent Adverse Events (TEAE)
ParticipantsARD-101Placebo Comparator
Acid reflux10
Nausea10
No TEAE reported126
SecondaryChange in TC

The change in total cholesterol (TC) at the end of treatment from baseline

Time frame:
Days 1 to 28
Reported as:
Mean · mg/dL
Change in TC
mg/dLARD-101Placebo Comparator
Change in TC-4.4 ± 17.325.7 ± 19.31
SecondaryChange in TG

The change in triglyceride (TG) at the end of treatment from baseline

Time frame:
Days 1-28
Reported as:
Mean · mg/dL
Change in TG
mg/dLARD-101Placebo Comparator
Change in TG-0.6 ± 93.810.5 ± 27.60
SecondaryChange in HDL

The change in high density lipoprotein cholesterol (HDL) at the end of treatment from baseline

Time frame:
Days 1-28
Reported as:
Mean · mg/dL
Change in HDL
mg/dLARD-101Placebo Comparator
Change in HDL0.2 ± 7.364.0 ± 6.10
SecondaryChange in LDL

The change in low-density lipoprotein cholesterol (LDL) at the end of treatment from baseline

Time frame:
Days 1-28
Reported as:
Mean · mg/dL
Change in LDL
mg/dLARD-101Placebo Comparator
Change in LDL-6.8 ± 16.951.3 ± 15.15
SecondaryChange in Waist Circumference

The change in waist circumference at the end of treatment from baseline

Time frame:
Days 1-28
Reported as:
Mean · cm
Change in Waist Circumference
cmARD-101Placebo Comparator
Change in Waist Circumference-0.2 ± 1.7-0.8 ± 3.3
SecondaryChange in % HbA1C

The change in % of hemoglobin A1c (HbA1c) at the end of treatment from baseline

Time frame:
Screening to Day 28
Reported as:
Mean · Percent of HbA1c
Change in % HbA1C
Percent of HbA1cARD-101Placebo Comparator
Change in % HbA1C-0.17 ± 0.22-0.18 ± 0.24

Adverse events

Collected over Six weeks (28-day treatment period plus 14-day follow-up post treatment). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARD-1010/14 (0%)0/14 (0%)3/14 (21.4%)
Placebo Comparator0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventARD-101Placebo Comparator
Foot InjuryInjury, poisoning and procedural complications0/141/6
Acid RefluxGastrointestinal disorders1/140/6
Back PainMusculoskeletal and connective tissue disorders1/140/6
NauseaGastrointestinal disorders1/140/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ARD-101Placebo ComparatorTotal
<=18 years000
Between 18 and 65 years9615
>=65 years505
Age, Continuous
Age, Continuous(years)ARD-101Placebo ComparatorTotal
Mean57 ± 1249 ± 955 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)ARD-101Placebo ComparatorTotal
Female10313
Male437
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARD-101Placebo ComparatorTotal
Hispanic or Latino112
Not Hispanic or Latino13518
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARD-101Placebo ComparatorTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American303
White9413
More than one race000
Unknown or Not Reported000
Body Weight
Body Weight(Kg)ARD-101Placebo ComparatorTotal
Mean95.4 ± 12.4101.6 ± 23.897.3 ± 16.2
BMI
BMI(kg/m^2)ARD-101Placebo ComparatorTotal
Mean34.1 ± 3.635.2 ± 5.534.5 ± 4.1
08

Study locations

1 site
  • Altman Clinical and Translational Research Institute, University of California, San Diego
    San Diego, California 92037, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Nov 2022, 11 months.

Results were first posted in Jan 2025, 2 years 2 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Nov 16, 2021
StartActual
Nov 15, 2021
Primary completionActual
Nov 9, 2022
CompletionActual
Nov 9, 2022
Results first posted
Jan 22, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05121441
Lead sponsor
Aardvark Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2021
Start date
Nov 15, 2021
Primary completion
Nov 9, 2022
Completion
Nov 9, 2022
Results posted
Jan 22, 2025
Last update
Jan 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denatonium acetate monohydrate

Start the discussion